124 related articles for article (PubMed ID: 1421397)
1. Presence of active and latent type 1 plasminogen activator inhibitor associated with porcine platelets.
Lang IM; Marsh JJ; Moser KM; Schleef RR
Blood; 1992 Nov; 80(9):2269-74. PubMed ID: 1421397
[TBL] [Abstract][Full Text] [Related]
2. The formation of complexes between human plasminogen activator inhibitor-1 (PAI-1) and sodium dodecyl sulfate: possible implication in the functional properties of PAI-1.
Gaussem P; Anglés-Cano E
Biochim Biophys Acta; 1991 Sep; 1079(3):321-9. PubMed ID: 1911857
[TBL] [Abstract][Full Text] [Related]
3. High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi.
Fay WP; Murphy JG; Owen WG
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1277-84. PubMed ID: 8857925
[TBL] [Abstract][Full Text] [Related]
4. Sodium dodecyl sulfate-induced dissociation of complexes between human tissue plasminogen activator and its specific inhibitor.
Gaussem P; Grailhe P; Anglés-Cano E
J Biol Chem; 1993 Jun; 268(16):12150-5. PubMed ID: 8505335
[TBL] [Abstract][Full Text] [Related]
5. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
Bijnens AP; Knockaert I; Cousin E; Kruithof EK; Declerck PJ
Thromb Haemost; 1997 Feb; 77(2):350-6. PubMed ID: 9157595
[TBL] [Abstract][Full Text] [Related]
6. Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells.
Sakata Y; Okada M; Noro A; Matsuda M
J Biol Chem; 1988 Feb; 263(4):1960-9. PubMed ID: 3123483
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets.
Torr-Brown SR; Sobel BE
Thromb Res; 1993 Dec; 72(5):413-21. PubMed ID: 8303684
[TBL] [Abstract][Full Text] [Related]
8. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator.
Kahr WH; Zheng S; Sheth PM; Pai M; Cowie A; Bouchard M; Podor TJ; Rivard GE; Hayward CP
Blood; 2001 Jul; 98(2):257-65. PubMed ID: 11435291
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitors in plasma and platelets from patients with recurrent venous thrombosis and pregnant women.
Häggroth L; Mattsson C; Felding P; Nilsson IM
Thromb Res; 1986 Jun; 42(5):585-94. PubMed ID: 3087015
[TBL] [Abstract][Full Text] [Related]
10. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1.
Gils A; Declerck PJ
J Biol Chem; 1997 May; 272(19):12662-6. PubMed ID: 9139722
[TBL] [Abstract][Full Text] [Related]
11. Demonstration of a functionally active tPA-like plasminogen activator in human platelets.
Wang DL; Pan YT; Wang JJ; Cheng CH; Liu CY
Thromb Haemost; 1994 Apr; 71(4):493-8. PubMed ID: 8052969
[TBL] [Abstract][Full Text] [Related]
12. Thrombin Provokes Degranulation of Platelet α-Granules Leading to the Release of Active Plasminogen Activator Inhibitor-1 (PAI-1).
Huebner BR; Moore EE; Moore HB; Stettler GR; Nunns GR; Lawson P; Sauaia A; Kelher M; Banerjee A; Silliman CC
Shock; 2018 Dec; 50(6):671-676. PubMed ID: 29280928
[TBL] [Abstract][Full Text] [Related]
13. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface.
Podor TJ; Singh D; Chindemi P; Foulon DM; McKelvie R; Weitz JI; Austin R; Boudreau G; Davies R
J Biol Chem; 2002 Mar; 277(9):7529-39. PubMed ID: 11744725
[TBL] [Abstract][Full Text] [Related]
14. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
15. Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line.
Wagner OF; Vetterlein M; Binder BR
J Biol Chem; 1986 Nov; 261(31):14474-81. PubMed ID: 3490474
[TBL] [Abstract][Full Text] [Related]
16. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus.
Braaten JV; Handt S; Jerome WG; Kirkpatrick J; Lewis JC; Hantgan RR
Blood; 1993 Mar; 81(5):1290-9. PubMed ID: 8443390
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor-1 complexes in human monocytes.
Simon DI; Xu H; Vaughan DE
Biochim Biophys Acta; 1995 Aug; 1268(2):143-51. PubMed ID: 7662701
[TBL] [Abstract][Full Text] [Related]
18. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants.
Hekman CM; Loskutoff DJ
J Biol Chem; 1985 Sep; 260(21):11581-7. PubMed ID: 3930479
[TBL] [Abstract][Full Text] [Related]
19. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate.
Urano T; Strandberg L; Johansson LB; Ny T
Eur J Biochem; 1992 Nov; 209(3):985-92. PubMed ID: 1425706
[TBL] [Abstract][Full Text] [Related]
20. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).
Declerck PJ; De Mol M; Alessi MC; Baudner S; Pâques EP; Preissner KT; Müller-Berghaus G; Collen D
J Biol Chem; 1988 Oct; 263(30):15454-61. PubMed ID: 2459123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
